Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.
    society-img

    Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury (beta)

    Official guideline from the American College of Gastroenterology.

    Summary by Maureen Whitsett, MD & Shannon Chang, MD
    Strength
    Strong recommendation
    Moderate recommendation
    Conditional recommendation
    Weak recommendation
    N/A
    Evidence
    High quality evidence
    Moderate-high quality evidence
    Moderate quality evidence
    Low quality evidence
    Very low quality evidence
    N/A

    Diagnosis

    Hepatocellular, Cholestatic, or Mixed
    1. Conduct a thorough history for temporal relationship and competing medications and substances. By convention, R≥5 is labeled as hepatocellular DILI, R<2 is labeled cholestatic DILI, and 2< R <5 is labeled “mixed” DILI. (R Factor for Liver Injury)
    2. Should exclude hep A, B, C, and autoimmune hepatitis with standard serologies and HCV RNA.
    3. Routine anti-HEV IgM testing is not recommended, but should consider if clinical suspicion (e.g. recent travel to endemic area).
    4. If atypical lymphocytosis and lymphadenopathy present and viral hepatitis panel negative, should test for acute HSV, CMV, EBV.
    5. Should consider Wilson’s and Budd-Chiari when clinically appropriate. Should screen for Wilson’s with ceruloplasmin, particularly in patients <40 years old. Consider additional workup (urine copper, slit-lamp exam) if strong clinical suspicion. Should consider Budd-Chiari especially if tender hepatomegaly and/or ascites.
    Cholestatic DILI
    1. Should perform abdominal imaging (CT or US) in all cases to rule out biliary tract pathology and infiltrative processes.
    2. Should limit testing for primary biliary cirrhosis to those with no obvious pathology on imaging.
    3. Should limit ERCP to cases where routine imaging cannot exclude impacted CBD stones, PSC, or pancreaticobiliary malignancy.
    Liver Biopsy
    1. Should consider liver biopsy if AIH is a competing etiology and immunosuppressive therapy considered.
    2. May consider liver biopsy if liver biochemistries keep rising or signs of worsening liver function despite stopping suspected offending drug.
    3. May consider liver biopsy if peak ALT fails to fall by >50% at 30-60 days after onset (hepatocellular DILI) or peak alk Phos fails to fall by >50% if cholestatic DILI by 180 days.
    4. May consider liver biopsy if continued use or re-exposure to the drug is expected.
    5. May consider liver biopsy if liver biochemistry abnormalities persist beyond 180 days and chronic DILI or chronic liver disease is suspected.

    Management

    Suspected Offending Agents
    1. Re-exposure to suspected offending agent is strongly discouraged, especially if significant aminotransferase elevation occurred (i.e., >5x ULN), Hy’s law, or jaundice. Exception is if the suspected agent is life-saving and no suitable alternative.
    2. Should promptly stop suspected offending agents liver biochemistries rising rapidly or if evidence of liver dysfunction.
    3. Little evidence exists supporting corticosteroid use in acute liver failure and there are no controlled trials examining the role of steroids in DILI.
    NAC
    1. No definitive therapies are available (idiosyncratic DILI with or without ALF), but may consider NAC in adults with early-stage ALF - good safety profile, some evidence for efficacy in early coma stage patients.
    2. NAC not recommended in children with ALF from severe DILI.
    Herbal and Dietary Supplements (HDS)
    1. Patients should be encouraged to report use of HDS and be reminded that supplements do not undergo the same safety and efficacy testing as prescription medications.
    2. Same diagnostic approach for DILI applies to HDS-hepatotoxicity. HDS is a diagnosis of exclusion and is more likely in the setting of recent HDS use.
    3. If HDS-hepatotoxicity is suspected, should stop all HDS and monitor for resolution of liver injury.
    DILI in Chronic Liver Disease (CLD)
    1. DILI in CLD requires high index of suspicion and exclusion of other more common causes of acute liver injury (e.g. flare-up of underlying disease).
    2. If using potentially hepatotoxic drugs in CLD patients, should base decision on risk vs benefit and on case-by-base basis.
    3. If prescribing potentially hepatotoxic medications to patients with CLD, counsel patients on promptly reporting any new symptoms. Additionally, consider monitoring liver biochemistries at 4-6 weekly intervals.
    What do the icons mean?  
    Research PaperChalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66.